Stem Cell Clinic

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data – Yahoo Finance

Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and confidential information to third parties who have no ownership or custodial right to it.

Hemostemix engaged the services of Accudata to conduct, pursuant to a Consulting Agreement executed in August 2019, a statistical analysis of the clinical trial midpoint data. All clinical trial data and, in particular, the clinical trial midpoint analysis and supporting data are, and always have been, the property of Hemostemix. Hemostemix has an absolute ownership right over that data and an absolute right to recover the data upon demand. Despite repeated requests, Accudata has failed and refused to return the midpoint data to Hemostemix.

Hemostemix also recently learned that, while refusing to return the clinical trial midpoint data to Hemostemix, Accudata produced a copy of the midpoint data and report to an agent of the former Contract Research Organization ("CRO"), Aspire Health Science, LLC ("Aspire") and Aspire is now blocking Hemostemix from obtaining the return of its clinical trial data. Neither Aspire nor any of its agents or representatives have any ownership or any other right to have, maintain, or withhold such data, or to hold such data to the exclusion of Hemostemix. Hemostemix seeks the Court's immediate intervention to enjoin Accudata's continued breaches of the parties' agreement.

Hemostemix filed in the United States District Court for the District of Delaware.

On June 25, 2020 counsel for Hemostemix presented oral argument to the 9th Circuit Court in and for Orange County, Florida on its motion to dismiss Aspire's lawsuit on grounds that, among other things, Hemostemix's threshold challenge that it is not subject to jurisdiction in Florida. A decision on Hemostemix's motion is pending. In the meantime, the presiding judge has stayed a hearing on Aspire's Motion for a Speedy Hearing previously set for June 29, 2020 pending a decision on Hemostemix's motion to dismiss.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-Founder TSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information regarding: the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any required or desired financings of Hemostemix, including TSX Venture Exchange acceptance and any third party consents; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Story continues

Read the original:
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data - Yahoo Finance

Transplant patient turns to art to raise money for charity which saved her life – Bishop’s Stortford Independent

A young Bishop's Stortford woman who suffers from a rare immune disorder has completed a challenge to paint every day for a month to raise money for the Anthony Nolan charity.

Michelle Peppiatt, 30, received a stem cell transplant last year after the organisation found her a matching donor and is now recovering at her home in Wallace Court where she has been shielding since before the coronavirus outbreak.

Art has proved a great outlet for Michelle in keeping her anxiety at bay and at the completion of her challenge yesterday (June 30) she had raised more than 700. "At the beginning of the month I decided to fundraise for Anthony Nolan, who save the lives of thousands with blood disorders. But I started to wonder how they were getting by during Covid-19 and it suddenly hit me that it could have been me and I might not have had my transplant so I decided to fundraise by taking art every day for the duration of June.

"Post transplant I really struggled to find things I was capable of doing due to the effects of the treatment and just stumbled across art and thought I would give it a go. I fell in love with it - it's been a great outlet for me."

Michelle's condition is known as Haemophagocytic lymphohistiocytosis (HLH), a rare immune disorder where the body reacts inappropriately to a trigger, usually an infection. There are two forms of HLH - primary which is a genetic type and secondary which is caused by a malignant blood cancer or acute infection/virus.

Michelle was diagnosed with lymphoma first and then the HLH was discovered. She said: "I had the treatment that is suggested for HLH which is eight weeks of chemotherapy and immune therapy. I relapsed three times after several rounds of chemotherapy immune therapy and biological therapies - my only chance at surviving was a stem cell transplant.

"The HLH had affected all my organs and muscles. But my medical team turned to Anthony Nolan to help. Anthony Nolan search every stem cell donor register in the world to find some one who is a perfect genetic match. I received my stem cell transplant in January 2019. I have long term effects of treatment and art helps me manage anxiety, pain, fatigue and isolation.

"I spent a number of weeks and months in isolation during treatment, due to infections and after the transplant. I'm adjusted to being sheilded and have learnt to keep myself occupied. I have had to find ways to manage my anxiety and general mental health."

Michelle describes her work as fluid art using acrylics and each day has picked a subject matter out of a pot. "Today was oceans and I made art based on the colours of the ocean. I've been painting every day, usually three paintings a day, and sell them via my Facebook page, but now we're at the end I'm looking to expand because they are still selling and I hope to reach more people," she said.

"And now that I have created a space for continuing after this I possibly will set it up as a business. "

She said the experience of lockdown "wasn't too bad as I have spent the last three and a half years in isolation" and discovering art had been a great help. "It has been incredibly therapeutic for me. It has no boundaries, it's very freeing."

On her Facebook posts, Michelle says: "At the start of this I did begin to wonder what I'd let myself in for. When I look at my paintings I've accomplished I feel something I haven't felt in a long time. Peace. A moment of mindfullness and connection!"

Michelle's remaining paintings will still be on sale until August 1. Visit @chelepep/freedomart on Facebook or her instagram page @chellepep for more details.

The rest is here:
Transplant patient turns to art to raise money for charity which saved her life - Bishop's Stortford Independent

Artificial Blood Substitutes Market – Insights into how contours of market will change in coming years – BioSpace

The global artificial blood substitutes market is predicted to register stellar growth rate in the forthcoming years. The presence of a large patient population that requires blood transfusion during surgeries, trauma, and for other blood disorders, which remains unmet due to shortage of blood supply has necessitated creation of artificial blood substitutes.

Artificial blood substitutes are primarily used to mimic oxygen carrying capacity of biological blood and expand the blood volume in the human body. Use of artificial blood substitutes is at present considered an alternate method for blood transfusion. Further research is underway to develop more alternate methods for blood transfusion, including developing human red blood cells (RBCs) from stem cells of donors blood.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5793

The research report provides an in-depth analysis of the artificial blood substitutes market over the forecast period. The report covers each and every key aspect pertinent to the market, including market dynamics, segmentation, and competitive scenario. The assessment of artificial blood substitutes market presented herein could serve as a valuable guide for both existing market participants, and the ones seeking entry in this market.

Artificial Blood Substitutes Market: Competitive Landscape and Notable Developments

The initial clinical trials for blood substitutes are recorded as early as early 1600, wherein milk, beer, urine, sheeps blood, and perfluorochemicals were administered as blood substitutes for animal and human subjects.

In successive periods, clinical trials of milk transfusion, including goats milk in large quantities were carried out but in vain. Clinical trials also involved injecting human milk that were futile too, which led researchers concede human milk not to be a substitute for blood.

With continual extensive research, over long periods, scientists have attained some success to develop blood substitutes. Artificial blood thus far developed can substitute red blood cells. While biological human blood performs several different functions, artificial blood performs the sole purpose of transporting oxygen and carbon dioxide in the body.

Established biotechnology companies in the ambit are engaged to develop blood substitutes. Such pursuits primarily involve developing oxygen carriers similar or above the capacity of biological blood. With concerted efforts of some top-notch biotechnology companies, namely HEMARINA SA, KaloCyte Inc. and Hemoglobin Oxygen Therapeutics LLC blood substitutes are available as oxygen carrier based on hemoglobin and perfluorocarbon-based oxygen carrier.

Nevertheless, presence of several well-established biotechnology companies engaged in the development of blood substitutes portrays a competitive yet moderately consolidated vendor landscape of the artificial blood substitutes market.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=5793&ltype=S

Artificial Blood Substitutes Market: Key Trends

Worldwide, excessive blood loss due to traumatic injuries and diseases is responsible for vast number of deaths every year. Limited availability of fresh blood and small storage periods of fresh blood for such situations have necessitated development of artificial blood substitutes.

With continual experiments over long periods, scientists have thus far been able to create substitutes to mimic oxygen carrier capacity of biological blood. Development of perfluorochemical-based oxygen carrier and hemoglobin-based oxygen carrier and provide thrust to the artificial blood substitutes market.

Besides this, advent of stem cell therapy is poised to create new opportunities for demand of artificial blood substitutes.

However, on the downside, lower shelf life of artificial blood products and stringent regulatory approval process for these products restrain the growth of artificial blood substitutes market.

Artificial Blood Substitutes Market: Regional Outlook

North America is at the fore for demand within overall artificial blood substitutes market. Presence of advanced healthcare combined with awareness of individuals for alternate demonstrated therapies account for leading revenue share of the region.

Continual advances in stem cell therapy further indicates sustained growth of artificial blood substitutes market in the region.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5793

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Follow this link:
Artificial Blood Substitutes Market - Insights into how contours of market will change in coming years - BioSpace

Global Stem Cell Therapy Market 2020 Segmentation, Top Manufacturers, Demand, Growth, Trend, Opportunity and Forecast to 2025 – 3rd Watch News

The global Stem Cell Therapy market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 18.9% in the forecast period of 2020 to 2025 and will expected to reach USD 828.7 million by 2025, from USD 415.3 million in 2019. The Stem Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Get Latest Sample for Global Stem Cell Therapy Market Report @ https://www.arcognizance.com/enquiry-sample/737506

Market segmentation Stem Cell Therapy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Stem Cell Therapy market has been segmented into Autologous, Allogeneic, etc.

By Application, Stem Cell Therapy has been segmented into Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others, etc.

Regions and Countries Level Analysis Regional analysis is another highly comprehensive part of the research and analysis study of the global Stem Cell Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Stem Cell Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Stem Cell Therapy market. The report offers in-depth assessment of the growth and other aspects of the Stem Cell Therapy market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Stem Cell Therapy markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Access Complete Global Stem Cell Therapy Market Report @ https://arcognizance.com/report/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Competitive Landscape and Stem Cell Therapy Market Share Analysis Stem Cell Therapy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Stem Cell Therapy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Stem Cell Therapy sales, revenue and market share for each player covered in this report.

The major players covered in Stem Cell Therapy are: Osiris Therapeutics, Molmed, JCR Pharmaceutical, NuVasive, Anterogen, Chiesi Pharmaceuticals, Medi-post, Pharmicell, Takeda (TiGenix), etc. Among other players domestic and global, Stem Cell Therapy market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Buy The Report @ https://www.arcognizance.com/purchase/737506

Major Point of TOC:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Company Profiles

Chapter Three: Market Competition, by Players

Chapter Four: Market Size by Regions

Chapter Five: North America Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East & Africa Revenue Stem Cell Therapy by Countries

Chapter Ten: Market Size Segment by Type

Chapter Eleven: Global Stem Cell Therapy Market Segment by Application

Chapter Twelve: Global Stem Cell Therapy Market Size Forecast (2021-2025)

To Check Discount of Stem Cell Therapy Market @ https://www.arcognizance.com/discount/737506

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.

ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact US: Name: Analytical research cognizance Address: 100 Church Street, 8th floor, Manhattan, New York 10007 Phone: +1 (646) 403-4695 +91 90967 44448 Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read the original post:
Global Stem Cell Therapy Market 2020 Segmentation, Top Manufacturers, Demand, Growth, Trend, Opportunity and Forecast to 2025 - 3rd Watch News

Duchenne Muscular Dystrophy Treatment Market to Witness over XX% Growth ‘in Revenue During the COVID-19 Pandemic Scenario – Kentucky Journal 24

Duchenne Muscular Dystrophy (DMD) is a muscle degeneration and is a genetic disorder which is X-linked recessive. However, it is also inherited from parents or caused due to a new mutation. There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.

Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the duchenne muscular dystrophy treatment. Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants and also the last-stage DMD patients. In the last few years, there has been rapid development in the duchenne muscular dystrophy therapeutics. However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness.

Duchenne Muscular Dystrophy (DMD) is a type of muscular disorder due to which most of the people are unable to walk at a very early stage and the affected muscles look larger due to the fat content. The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability. Although, the treatment to control and reduce the signs and symptoms is available, yet there is no cure for DMD. Key players in the market are also trying to spread awareness about DMD along with the investment in finding a treatment for the disease. Meanwhile, human clinical trials are also underway to find out effective therapy.

Request For Report Sample:http://marketgrowthanalysis.com/reports/sample/211

Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy. Meanwhile, there is an ongoing research on gene therapy, exon skipping drugs, and stem cell therapy to treat duchenne muscular dystrophy in a better way. Current pharmacological interventions for duchenne muscular dystrophy include approaches to mitigate downstream and secondary pathological mechanisms and solutions targeting primary defect. Patients with DMD are not able to produce a protein known as dystrophin. Hence, a variety of new medications are being developed to replace dystrophin. Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin. However, delay in diagnosis and the high cost of treatment and drugs are some of the factors restricting the growth of the market.

The global duchenne muscular dystrophy market is segmented into therapy, distribution channel, product type, and region. The product type is further segmented into corticosteroids, NSAIDs, and other products. Among these, corticosteroids are likely to witness the highest growth during the forecast period. By the end of 2026, corticosteroids are estimated to bring in more than US$ 9,000 million revenue.

Based on the distribution channel, the global duchenne muscular dystrophy market segmentation includes online pharmacies, retail pharmacies, and hospital pharmacies. Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market. Hospital pharmacies are anticipated to exceed US$ 6,000 million revenue towards the end of 2026.

On the basis of therapy, the market segmentation includes Exon Skipping Approach, Mutation Suppression, and other therapies. Mutation suppression therapy is expected to witness strong growth throughout the forecast period. By the end of 2026, mutation suppression therapy is estimated to bring in more than US$ 6,400 million revenue.

Request For COVID-19 Analysis:http://marketgrowthanalysis.com/reports/enquiry/211

Europe is expected to be the dominating region in the global duchenne muscular dystrophy market during the forecast period. Owing to the high rate of people suffering from duchenne muscular dystrophy, Europe is witnessing the growth in adoption of treatment for muscular dystrophy. Also, various treatments are approved or under review to treat duchenne muscular dystrophy in Europe. This is also one of the reasons for the growth of the market in Europe.

Some of the players in Duchenne Muscular Dystrophy Treatment Market are Bristol-Myers Squibb(U.S), FibroGen, Inc (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc.(U.S) , NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co (Japan), Sarepta Therapeutics (U.S), Inc., Santhera Pharmaceuticals, PTC Therapeutics (Switzerland)

Request For Report TOC:http://marketgrowthanalysis.com/reports/toc/211

View post:
Duchenne Muscular Dystrophy Treatment Market to Witness over XX% Growth 'in Revenue During the COVID-19 Pandemic Scenario - Kentucky Journal 24

Hodgkin’s Lymphoma in 8 Major Markets, 2019-2029 – Anticipated Label Expansions of Currently Marketed Therapies is a Key Driver – GlobeNewswire

July 03, 2020 06:24 ET | Source: Research and Markets

Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Hodgkin's Lymphoma - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

The World Health Organization (WHO) classifies HL into two main types: classical HL (CHL) and nodular lymphocyte-predominant HL (NLPHL), which CHL accounts for 95% of cases. Historically, treatment of HL has been mostly reliant on chemotherapies, radiotherapy and SCT and has lacked a rapidly advancing pipeline.

In recent years however, the arrival of three novel agents reflect a change in the treatment paradigm, shifting from cytotoxic therapies to immunotherapies and novel cell-based therapies.

The publisher is expecting a total of 6 new entrants to launch over the forecast period in the 8MM from 2019-2029, while specific marketed agents are expected to move into earlier lines of treatment as novel combinations. The main competition will between drug entering the first-line setting and novel combinations within the salvage setting for relapsed and refractory patients. Given the high cure rate for this indication, these two early setting are the most determinant of global sales for Hodgkin's lymphoma.

Key Highlights

Report Scope

Key Questions Answered

Key Topics Covered

1 Table of Contents 1.1 List of Tables 1.2 List of Figures

2 Hodgkin's Lymphoma: Executive Summary 2.1 Moderate Market Growth Expected for Hodgkin's Lymphoma During 2019-2029 2.2 Drug Developers Focusing On Combination Therapies Featuring Marketed Products with Novel Therapies 2.3 Need for More Effective Therapies to Reduce the Use of Chemotherapy and Delay Stem Cell Transplant is Partially Attainable 2.4 Growth in the 8MM Is Driven by Label Expansions of Existing Therapies and Less Impacted by Novel Agents 2.5 What Do Physicians Think?

3 Introduction

4 Disease Overview 4.1 Etiology and Pathophysiology 4.2 Diagnosis and Symptoms

5 Epidemiology 5.1 Disease Background 5.2 Risk Factors and Comorbidities 5.3 Global and Historical Trends 5.4 Forecast Methodology 5.4.1 Sources 5.4.2 Sources Not Used 5.5 Forecast Assumptions and Methods 5.5.1 8MM 5.6 Epidemiological Forecast for HL (2019-2029) 5.6.1 Diagnosed Incident Cases of HL 5.6.2 Diagnosed Incident Cases of Classical HL 5.6.3 Age-Specific Diagnosed Incident Cases of Classical HL 5.6.4 Sex-Specific Diagnosed Incident Cases of Classical HL 5.6.5 Diagnosed Incident Cases of Classical HL by Cancer Stage 5.6.6 Diagnosed Incident Cases of Classical HL by Cancer Subtypes 5.6.7 Five-Year Diagnosed Prevalent Cases of Classical HL 5.6.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant HL 5.7 Discussion 5.7.1 Epidemiological Forecast Insight 5.7.2 Limitations of the Analysis 5.7.3 Strengths of the Analysis

6 Current Treatment Options 6.1 Treatment Overview

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7tkcvl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Formats available:

The rest is here:
Hodgkin's Lymphoma in 8 Major Markets, 2019-2029 - Anticipated Label Expansions of Currently Marketed Therapies is a Key Driver - GlobeNewswire

Potential Impact of COVID-19 on Research report explores the Autoimmune Disorders Treatment Market for the forecast period, 2020-2026 – 3rd Watch News

Autoimmune Disorders Treatment Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Sanofi, Merck, Pfizer) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Autoimmune Disorders Treatment industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Autoimmune Disorders Treatment Market describe Autoimmune Disorders Treatment Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.

Key Target Audience of Autoimmune Disorders Treatment Market:Manufacturers of Autoimmune Disorders Treatment, Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Autoimmune Disorders Treatment market.

Get Free Sample PDF (including full TOC, Tables and Figures)of Autoimmune Disorders Treatment[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2374588

In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Autoimmune Disorders Treatment Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.

Summary of Autoimmune Disorders Treatment Market:Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in women than in men, which results from the influence of estrogen on immune system.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Autoimmune Disorders Treatment market foreach application, including-

Systemic autoimmune diseases Localized autoimmune diseases

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Bridge therapy Recombinant technology Fecal bacteriotherapy Hematopoietic stem-cell transplantation Phototherapy Helminthic therapy Activation-induced assays Cytometry by time-of-flight mass spectrometry

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2374588

Important Autoimmune Disorders Treatment Market Data Available In This Report:

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://bit.ly/2Sepby2

Go here to read the rest:
Potential Impact of COVID-19 on Research report explores the Autoimmune Disorders Treatment Market for the forecast period, 2020-2026 - 3rd Watch News